Internal dosimetry studies of Lu-BBN-GABA-DOTA, as a cancer therapy agent, in human tissues based on animal data.

The goal of using radiopharmaceuticals for therapeutic purposes is twofold: first, the most damage to cancer cells and, second, the most negligible dose transfers to healthy tissues. As Lu has the potential to cure a wide range of malignancies due to its varied range of beta energies, Lu-BBN-GABA-DOTA has been developed for therapeutic applications. In addition, Lu-BBN-GABA-DOTA can be over-expressed on gastrin-releasing peptide (GRP) receptors of the prostate, breast, small cell lung cancer, gastric, and colon tumors.

A new formulation of polymer gel dosimeter with reduced toxicity: Dosimetric characteristics and radiological properties.

The present study aimed to produce a new, less toxic, and cost-effective polymer gel dosimeter using potassium salt of 2-acrylamido-2 methyl-propane sulfonic acid (AMPS) monomer. The new formulation was called PAKAG. The irradiation of PAKAG polymer gel dosimeter was performed using a 6 MV clinical linear accelerator, and its response was evaluated using magnetic resonance imaging.

3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.

Various methods, such as those developed by the Medical Internal Radiation Dosimetry (MIRD) Committee of the Society of Nuclear Medicine or employing dose point kernels, have been applied to the radiation dosimetry of (131)I radionuclide therapy. However, studies have not shown a strong relationship between tumour absorbed dose and its overall therapeutic response, probably due in part to inaccuracies in activity and dose estimation. In the current study, the GATE Monte Carlo computer code was used to facilitate voxel-level radiation dosimetry for organ activities measured in an (131)I-treated thyroid cancer patient.